Sperogenix Therapeutics is a platform company dedicated to developing and commercializing rare disease therapeutics in China with focus on mid-to-late clinical stage and commercial stage products. With prioritized therapeutic areas, such as Pulmonary Vascular Disorders, Neurological Disorders, Inherited Metabolic Diseases, and Non-oncology Hematology Disorders, Sperogenix is dedicated to establishing an innovative commercial model tailored to the China rare disease field, in order to provide affordable and reliable products and services to Chinese physicians and patients. Sperogenix was founded in 2019 and is backed by biopharma industry blue chip investors including Lilly Asia Ventures (LAV) and Morningside Venture in the A-round financing.
Company Details
- Employees
- 15
- Founded
- -
- Address
- 朝阳区东直门外大街小关56号5幢二层216室, 北京,北京 100025,china
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- sperogenix.com
- HQ
- 北京, 北京
Sperogenix Therapeutics 曙方医药 Questions
Sperogenix Therapeutics 曙方医药's website is sperogenix.com
Sperogenix Therapeutics 曙方医药's LinkedIn profile is https://cn.linkedin.com/company/sperogenix
Sperogenix Therapeutics 曙方医药 has
15 employees.
View email and phone details for 15
employees at Sperogenix Therapeutics 曙方医药.
Sperogenix Therapeutics 曙方医药's industry is
Pharmaceutical Manufacturing
Sperogenix Therapeutics 曙方医药's top competitors are
Simcere Pharmaceutical Group,
Asieris Pharmaceuticals,
Be Biopharma,
Genequantum Healthcare (Suzhou) Co., Ltd,
Neurofront Therapeutics Limited,
Zhejiang Hisun Pharmaceutical Co Ltd,
海默尼药业,
瀚晖制药 Hanhui Pharmaceuticals,
Astellas Pharma,
Metis Therapeutics.
Sperogenix Therapeutics 曙方医药's categories are Pharmaceutical Manufacturing
Sperogenix Therapeutics 曙方医药's founding year is 2019
